RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
RU58841 powder from a lab supplier was tested at a free drug testing service. The discussion includes using Minoxidil and finasteride for hair loss treatment.
The conversation discusses the use of trichoscopy to predict hair loss patterns and inform treatment approaches. Treatments mentioned include minoxidil, finasteride, and dutasteride, with varying effectiveness based on gender-specific hair loss patterns.
The conversation discusses a hair loss treatment regimen that includes a topical spray with finasteride and minoxidil, tretinoin, and using a Derminator (microneedling device) at 1.25mm depth every 5-6 days. The user reports positive results after 90 days and plans to continue the treatment, with others commenting on the process and potential outcomes.
OP shared a 1-month progress update on using a topical solution with dutasteride, minoxidil, and tretinoin for hair loss. Users noted regrowth and discussed tretinoin's availability.
A 27-year-old shared progress 6 months after a hair transplant of 4500 grafts, using finasteride and minoxidil. The procedure was done at Vera Clinic in Istanbul, costing 3000 Euros, and the user is pleased with the results.
The user experienced significant hair regrowth with finasteride but stopped due to libido issues. They are now considering using minoxidil, dermarolling, and Nizoral to maintain their hairline.
A user's progress in treating their hair loss with Finasteride, Minoxidil and Dermarolling; they discussed details of their routine and others congratulated them on their success.
The conversation is about using tretinoin to enhance the effectiveness of minoxidil for hair loss. Tretinoin should be applied at night on dry skin, and it can be used daily, either before or after minoxidil, with a starting dose of 0.025%.
Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.
RU58841 helped reduce scalp itching for some users within a week, while others experienced immediate relief. Some users reported initial irritation from the solution, possibly due to the carrier used.
The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.
A 42-year-old male shared his 5-month progress using oral dutasteride, oral and topical minoxidil, and dermarolling for hair regrowth. He reported significant improvement and discussed the potential for further progress and maintenance, while addressing concerns about the safety of his minoxidil dosage.
The conversation discusses using Pyrilutamide, Alfatradiol 0.1%, and Minoxidil for hair loss treatment. Pyrilutamide is described as a strong antiandrogen, and Alfatradiol is noted for its effectiveness in inhibiting DHT on the scalp.
The user discusses their hair regrowth success with minoxidil, red light therapy, massage, and derma stamping but expresses concerns about using finasteride due to potential side effects. They are interested in using clascoterone as a topical treatment for hair loss and are exploring the possibility of creating a topical formula from raw clascoterone powder.
A 29-year-old male shared his hair growth progress after 3.5 months using finasteride, minoxidil (topical and orally), tretinoin cream, GHK-Cu, and derma stamping. He experienced increased libido initially and thinning body hair but is satisfied with the results despite an early shedding phase.
RU58841 remains active for several hours after application, and it's suggested to wait a few hours before washing it off to maintain its effectiveness. There is a concern about potential transfer to others if they touch the hair shortly after application.
Hair loss treatments, including Alfatradiol, Minoxidil, Finasteride, and RU58841. It discusses the efficacy of these treatments for hair growth and regrowth.
Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.
A 28-year-old male has been using oral finasteride and minoxidil for over a year without seeing significant results in hair thickness, particularly in the front. He is considering adding dermastamping to his routine and is exploring whether topical treatments might be more effective.
Matt-3422 shared his hair loss treatment journey, starting with great results from Minoxidil and oral Finasteride, then switching to RU58841 and topical Finasteride due to worsening hair loss. He's experiencing scalp irritation and is unsure if he should continue with his current regimen, while others suggest scalp care and alternative treatments.
Switching from finasteride to dutasteride can reduce scalp DHT levels more effectively. The discussion includes using minoxidil, finasteride, and RU58841 for hair loss treatment.
The user is pleased with their hair transplant results but is concerned about the vertex area. They use Minoxidil and finasteride daily and had the procedure at a clinic in Athens.
The user is using RU58841, Minoxidil, and weekly microneedling for hair loss, having stopped finasteride due to side effects like low libido and depression. They are considering dutasteride as an alternative but are cautious due to past experiences with DHT blockers.
The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.
A 35-year-old shared a 7-day update on their hair transplant, which involved 3,153 grafts performed by Dr. Elif at HLC Ankara, costing 10,000 euros including accommodations. The user has been on finasteride for over 12 years and opted for a partial shave FUE to address hairline recession and temple peaks.
A person shares their 10-month hair loss treatment progress using finasteride 1.25 mg daily, topical minoxidil 5% daily, weekly dermarolling with a 1.5mm device, and RU58841 for one month, encouraging others not to give up despite slow results. They noticed their progress after comparing past photos.
The user is using Minoxidil, finasteride, Nizoral, and dermarolling for hair loss but is not seeing results. They are considering trying a product called "capilia longa" for beard growth and are questioning its effectiveness.
Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.